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ABSTRACT 
Objective. Clinical genetic testing is commercially available for rs61764370, an inherited 
variant residing in a KRAS 3′ UTR microRNA binding site, based on suggested associations with 
increased ovarian and breast cancer risk as well as with survival time. However, prior studies, 
emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated 
ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.  
Methods. Centralized genotyping and analysis was performed for 140,012 women enrolled 
in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), 
the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and 
the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7,904 BRCA2 mutation 
carriers).  
Results. We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94–1.04, 
p=0.74) or breast cancer (OR=0.98, 95% CI 0.94–1.01, p=0.19) and results were consistent 
among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97–1.23, p=0.14, breast 
cancer HR=1.04, 95% CI 0.97–1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71–1.13, 
p=0.34, breast cancer HR=1.06, 95% CI 0.94–1.19, p=0.35). Null results were also obtained for 
associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83–1.07, p=0.38), 
breast cancer (HR=0.96, 95% CI 0.87–1.06, p=0.38), and all other previously-reported 
associations.  
Conclusions. rs61764370 is not associated with risk of ovarian or breast cancer nor with 
clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical 
utility related to the prediction or management of these cancers.  
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INTRODUCTION 
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that negatively 
regulate gene expression by binding partially complementary sites in the 3′ untranslated regions 
(UTRs) of their target mRNAs. In this way, miRNAs control many cancer-related biological 
pathways involved in cell proliferation, differentiation, and apoptosis [1]. To date, several inherited 
variants in microRNAs or miRNA target sites have been reported to confer increased cancer risks 
[2]. One such variant is located in the 3′ UTR of the KRAS gene (rs61764370 T>G) for which the 
rarer G allele has been reported to confer an increased risk of ovarian, breast, and lung cancer [3-
7] as well as endometriosis [8], although not consistently [9-11].  
For ovarian cancer, the rs61764370 G allele was also reported to be associated with 
increased risk (320 cases, 328 controls). Further increased risks were observed among 23 BRCA1 
mutation carriers and 31 women with familial ovarian cancer, but without BRCA1 or BRCA2 
mutations [3]. In contrast, no association with ovarian cancer risk was seen in another, much larger 
study, based on 8,669 cases, 10,012 controls, and 2,682 BRCA1 mutation carriers [9]. One 
criticism on the latter study was that some of the genotype data were for rs17388148, an imputed 
proxy for rs61764370; even though rs17388148 is highly correlated with rs61764370 (r2=0.97) and 
was imputed with high accuracy (r2=0.977) [12, 13]. The minor allele of rs61764370 was also 
associated with shorter survival time in a study of 279 ovarian cancer patients diagnosed after age 
52 years with platinum-resistant disease (28 resistant, 263 not resistant) and with sub-optimal 
debulking surgery after neoadjuvant chemotherapy (7 sub-optimal, 109 optimal) [14]. However, 
another study observed no association between rs61764370 and  ovarian cancer outcome (329 
cases) [15].  
For breast cancer, a borderline significant increased frequency of the rs61764370 G allele 
was observed in 268 BRCA1 mutation carriers with breast cancer, but not in 127 estrogen receptor 
(ER)-negative familial non-BRCA1/BRCA2 breast cancer patients [5]. However, in a subsequent 
study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 
cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 
cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has 
been questioned given the very small sample sizes and the number of subgroups tested [16, 17]. 
21 
 
Another report found no association with sporadic or familial breast cancer risk (695 combined 
cases, 270 controls), but found that the variant was associated with ERBB2-positive and high 
grade disease, based on 153 cases who used post-menopausal hormone replacement therapy 
[18].  
It has also been reported, based on 232 women with both primary ovarian and breast 
cancer, that the frequency of the G allele at rs61764370 was increased for those who were 
screened negative for BRCA1 and BRCA2 (92 cases), particularly among those enrolled within two 
years of their ovarian cancer diagnosis (to minimize survival bias, 30 cases), those diagnosed with 
post-menopausal ovarian cancer (63 cases), those with a family history of ovarian or breast cancer 
(24 cases), and those with a third primary cancer (16 cases) [4].  
This notable lack of consistency in findings between studies might be expected when 
appropriate levels of statistical significance are not used to declare positive findings from multiple 
small subgroup comparisons or post-hoc hypotheses [19]. In this respect, the dangers of subgroup 
analyses in the context of clinical trials are well-recognized [20]. These are important caveats, 
particularly since a genetic test for rs61764370 is currently marketed in the US for risk prediction 
testing to women who are at increased risk for developing ovarian and/or breast cancer or women 
who have been diagnosed with either ovarian or breast cancer themselves [21]. In general, much 
larger studies, with sufficient power to detect positive findings at much more stringent levels of 
statistical significance ought to be required to establish the clinical validity of a genetic test. 
Therefore, we conducted centralized genotyping of rs61764370 and other variants in the genomic 
region around the KRAS gene in 140,012 women to examine associations with risk and clinical 
outcome of ovarian and breast cancer.  
 
METHODS 
Study Participants  
The following three consortia contributed to these analyses: the Ovarian Cancer 
Association Consortium (OCAC: 41 studies, Supplementary Table S1) [22], the Breast Cancer 
Association Consortium (BCAC: 37 studies, Supplementary Table S2) [23], and the Consortium of 
Modifiers of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table S3) [24, 25]. OCAC 
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and BCAC consisted of case-control studies of unrelated women, and CIMBA consisted of studies 
of women with germline deleterious BRCA1 or BRCA2 mutations primarily identified through 
clinical genetics centers. For the purpose of the current analyses, only participants of European 
ancestry were included. Following genotyping, quality control exclusions (described below), and 
analysis-specific exclusions, data from the following women were available for analysis: 46,173 
OCAC participants (15,357 patients with invasive epithelial ovarian cancer and 30,816 controls), 
71,170 BCAC participants (33,530 patients with invasive breast cancer and 37,640 controls), and 
22,669 CIMBA participants (for ovarian cancer analyses: 2,332 affected and 12,433 unaffected 
BRCA1 carriers, 599 affected and 7,305 unaffected BRCA2 carriers; for breast cancer analyses: 
7,543 affected and 7,222 unaffected BRCA1 carriers, 4,138 affected and 3,766 unaffected BRCA2 
carriers). For OCAC, overall and progression-free survival data were available for 3,096 patients 
from 13 studies. Overall survival data were available for 28,471 patients from 26 BCAC studies 
and for 2,623 mutation carriers with breast cancer from 11 CIMBA studies (excluding studies with 
less than ten deaths) as described previously [26, 27]. Each study was approved by its relevant 
governing research ethics committee, and all study participants provided written informed consent. 
 
Genotyping and Imputation  
Genotyping for rs61764370 was performed using the custom iCOGS Illumina Infinium 
iSelect BeadChip, as previously described [22-25]. In total, DNA from 185,443 women of varying 
ethnic background was genotyped (47,630 OCAC participants, 114,255 BCAC participants, 23,558 
CIMBA participants), along with HapMap2 DNAs for European, African, and Asian populations. 
Genotype data were also available for three OCAC genome-wide association studies (UK GWAS, 
US GWAS, Mayo GWAS) that had been genotyped using either the Illumina Human610-Quad 
Beadchip (12,607 participants) [28] or the Illumina HumanOmni2.5-8 Beadchip (883 participants). 
Raw intensity data files underwent centralized genotype calling and quality control [22-25]. 
HapMap2 samples were used to identify women with predicted European intercontinental ancestry; 
among these women, a set of over 37,000 unlinked markers was used to perform principal 
component (PC) analysis [29]. The first five and seven European PCs were found to control 
adequately for residual population stratification in OCAC and BCAC data, respectively. Samples 
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with low conversion rate, extreme heterozygosity, non-female sex, or one of a first-degree relative 
pair (the latter for OCAC and BCAC only) were excluded. Variants were excluded if they were 
monomorphic or had a call rate <95% (minor allele frequency (MAF) >0.05) or <99% (MAF <0.05), 
deviation from Hardy-Weinberg equilibrium (p <10-7), or >2% duplicate discordance.  
In addition to rs61764370, 54 variants within 100 kb on either side of KRAS on 
chromosome 12 (25,258,179 to 25,503,854 bp in GRCh37.p12) were genotyped. Moreover, to 
provide a common set of variants across the region for analysis in all the data sets, we also used 
imputation to infer genotypes for another 1,056 variants and for variants that failed genotyping.  
We performed imputation separately for OCAC samples BCAC samples, BRCA1 mutation carriers, 
BRCA2 mutation carriers, and for each of the OCAC GWAS. We imputed variants from the 1000 
Genomes Project data using the v3 April 2012 release as the reference panel [30]. To improve 
computation efficiency we initially used a two-step procedure, which involved pre-phasing using 
the SHAPEIT software [31] in the first step and imputation of the phased data in the second. We 
used the IMPUTE version 2 software [32] for the imputation for all studies with the exception of the 
US GWAS for which we used the MACH algorithm implemented in the minimac software version 
2012.8.15 and MACH version 1.0.18 [33]. We excluded variants from association analyses if their 
imputation accuracy was r2<0.30 or their MAF was <0.005, resulting in 974 variants genotyped and 
imputed for OCAC, 989 variants genotyped and imputed for BCAC, and 1,001 variants genotyped 
and imputed for CIMBA, including rs61764370 (Supplementary Tables S5, S6, and S7).  
 
Analysis   
Genotypes were coded for genotype dosage as 0, 1, or 2, based on the number of copies 
of the minor allele. For ovarian cancer case-control analysis (i.e., OCAC studies), logistic 
regression provided estimated risks of invasive epithelial ovarian cancer with odds ratios (ORs) 
and 95% confidence intervals (CIs) adjusting for study, age, and the five European PCs. Subgroup 
analyses were conducted by histology, family ovarian and breast cancer history, menopausal 
status, time between ovarian cancer diagnosis and recruitment, and history of multiple primary 
cancers. For breast cancer case-control analysis (i.e., BCAC studies), the association between 
genotype and invasive breast cancer risk was evaluated by logistic regression, adjusting for study, 
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age, and the seven European PCs, providing ORs and 95% CIs. Additional subgroup analyses 
were based on receptor status, first-degree family ovarian and breast cancer history, BRCA1 and 
BRCA2 mutation status, enrollment within two years of diagnosis, menopausal status (i.e. last 
menstruation longer than twelve months ago), age at diagnosis less than 52 years, and history of 
hormone replacement therapy use (i.e. longer than twelve months use). Risk analysis for BRCA1 
and BRCA2 mutation carriers (i.e. CIMBA studies) was done using a Cox proportional hazard 
model to estimate hazard ratios (HRs) per copy of the minor allele, with age as follow-up time and 
stratified by country of residence; US and Canadian strata were further subdivided by self-reported 
Ashkenazi Jewish ancestry [24, 25]. A weighted cohort approach was applied to correct for 
potential testing bias due to overrepresentation of cases in the study population [34]. We used 
robust variance estimation to allow for the non-independence of carriers within the same family 
[35]. To assess associations with ovarian cancer risk, mutation carriers were followed from birth 
until ovarian cancer diagnosis (event), a risk-reducing salpingo-oophorectomy (RRSO) or the age 
at enrollment, whichever occurred first. We also performed analyses restricted to women 
diagnosed or censored within two years before their enrollment. To assess associations with 
breast cancer risk, mutation carriers were followed from birth until a breast cancer diagnosis (i.e. 
either ductal carcinoma in situ or invasive breast cancer), ovarian cancer diagnosis, a risk-reducing 
bilateral prophylactic mastectomy or the age at enrollment, whichever occurred first. 
Survival analysis of OCAC patients used Cox proportional hazards models estimating HRs 
and 95% CIs considering overall survival as well as progression-free survival following ovarian 
cancer diagnosis. Overall survival was adjusted for age at diagnosis, the five European PCs, 
histology, grade, FIGO stage, residual disease after debulking surgery, and stratified by study, left 
truncating at the date of study entry and right censoring at five years to minimize events due to 
other causes. Progression-free survival was analyzed as for overall survival, but without 
adjustment for age and right censoring, and was defined as the time between the date of histologic 
diagnosis and the first confirmed sign of disease recurrence or progression, based on GCIG 
(Gynecological Cancer InterGroup) criteria [36]. We also performed subgroup analysis of patients 
suboptimally debulked after cytoreductive surgery (residual disease >1cm) and of post-
menopausal patients (age at diagnosis >52 years). Survival analysis of BCAC patients used Cox 
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proportional hazard models estimating HRs and 95% CIs considering overall and breast cancer-
specific survival following breast cancer diagnosis. Models were adjusted for age at diagnosis, 
tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and stratified by study, 
left-truncating at the date of study entry and right censoring at ten years. In addition, we performed 
subgroup analysis on ER-positive and ER-negative patients. For CIMBA breast cancer patients 
associations between genotype and overall survival were evaluated using Cox proportional hazard 
models estimating HRs and 95% CIs. Models were adjusted for age at diagnosis, tumor size, nodal 
status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and 
stratified by study, left-truncating at the date of study entry and right censoring at twenty years. 
Analyses were performed using STATA version 12.0 (StataCorp, Texas, USA).  
 
RESULTS 
The results of the overall analysis as well as the subgroup analyses investigating the 
association between the minor allele at rs61764370 and ovarian cancer risk, breast cancer risk, 
and ovarian and breast cancer risks in BRCA1 and BRCA2 mutation carriers are shown in Table 1. 
Associations with clinical outcomes in and ovarian and breast cancer patients including BRCA1 
and BRCA2 mutation carriers are shown in Table 2 and Supplementary Table S4.  
We found no evidence for association between the rs61764370 G allele and ovarian or 
breast cancer risk. The most statistically significant association was observed for risk of low-grade 
serous ovarian cancer (n=485; OR 0.76, 95% CI 0.59-0.97, p=0.031), but this finding was not 
significant after Bonferroni correction for multiple testing. We also evaluated the association for 
additional specific subgroups in which an association with rs61764370 had been reported 
previously [3-6]. Ovarian cancer subgroups considered BRCA1 mutation carriers as well as 
BRCA1 and BRCA2 screened-negative patients with first degree family histories of breast or 
ovarian cancer and patients who had been diagnosed with breast cancer before their ovarian 
cancer diagnoses. For breast cancer these included, amongst others, BRCA1 mutation carriers, 
patients diagnosed with ER- and PR-negative tumors, and patients diagnosed with triple negative 
tumors before age 52 years. Importantly, we observed no evidence for association of rs61764370 
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with any of these subgroups (detailed in Table 1), with all ORs close to unity and very narrow CIs 
including unity. 
Similarly, case-only analyses did not reveal any associations between rs61764370 
genotype and ovarian and breast cancer clinical features or outcome (Table 2 and Supplementary 
Table S4). For example, the previously reported association between rs61764370 and risk of 
ERBB2-positive and high grade breast cancer in hormone replacement therapy users [18] was not 
replicated (Supplementary Table S4), and in ovarian cancer analyses we found no evidence of 
reduced survival among patients diagnosed after age 52 years or patients with suboptimal 
debulking after cytoreductive surgery (Table 2) [14]. The G allele of rs61764370 was also not 
associated with survival of breast cancer patients (Table 2). 
Finally, we evaluated the association between the primary phenotypes of interest and 
common genetic variation (MAF>0.02) in the genomic region of KRAS (i.e., within 100 kb on either 
side of the gene), using imputed and genotyped data on 974 variants for OCAC, 989 variants for 
BCAC, and 1,001 variants genotyped and imputed for CIMBA (Supplementary Tables S5, S6, and 
S7). We found no evidence of association for any of these variants, including rs61764370 and 
rs17388148, with these phenotypes that would withstand Bonferroni correction for multiple testing, 
as detailed in Supplementary Tables S5, S6, and S7 and shown in regional association plots 
(Figure 1). 
 
DISCUSSION 
Our analysis of 140,012 women genotyped for inherited variants in the KRAS region 
provides definitive clarification of the role of these variants in ovarian and breast cancer 
susceptibility and outcome.  We have found no evidence to support an association between 
rs61764370 and ovarian or breast cancer risk, or clinical outcomes in patients with ovarian or 
breast cancer. In the absence of any association and with ORs close to unity we would not 
typically consider sub-group analyses, particularly sub-groups for which differential associations 
would not be expected to occur. However, given the previous positive associations reported for a 
myriad of different subgroups, we tested for association among each of these subgroups and 
found no evidence to support the previously reported associations.   
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Our study has notable strengths. The vast majority (i.e. >95%) of the samples were 
genotyped using the same genotyping platform and employing a common approach to genotype 
calling and quality control; additional samples used denser arrays and nearly identical procedures. 
The very large sample sizes for all the major phenotypes of interest provide substantial statistical 
power to exclude any clinically relevant associated risks for the major phenotypes of interest 
(Figure 2). The null results found here are thus not due to lack of statistical power, and this 
analysis also had greater than 80% power to detect association for most of the subgroups, 
although for some subgroups it was not possible to exclude modest risks. In contrast to the current 
findings, other genetic association analyses using the same genotyping platform and the same 
studies as included here have identified more than 90 common germline variants associated with 
ovarian or breast cancer risk at p< 5 x 10-8 [22, 23, 37]. While critiques on a previous null KRAS 
report have suggested that inclusion of male controls, use of “prevalent” cases, and reliance on a 
surrogate genetic variant may have led to falsely negative conclusions, these are not issues in the 
present data set. Rather, we demonstrate the importance of international collaboration to identify 
true associations as well as to refute false associations, an equally important objective. 
The rise of individualized medicine including the use of panels of common variants to 
predict cancer risk more accurately than using family history alone holds great promise [38]. For 
example, the 31 prostate cancer susceptibility alleles confirmed as of 2011 can be combined to 
identify men in the top one percent of the risk distribution having a 3.2-fold increased risk [39]. 
Prediction has since then improved with now over 70 prostate cancer susceptibility alleles [40] and 
the utility of these genetic tests is currently under clinical evaluation. Similar clinical examination in 
ovarian and breast cancer is not far behind, with now over 18 and 77 confirmed susceptibility 
alleles, respectively, for these cancers [22, 23]. The genotype at rs61764370, however, does not 
predict ovarian or breast cancer risk, even among particular subgroups of women or for particular 
subtypes of disease, nor is it a marker of differential outcome following diagnosis with these 
cancers. Therefore, genetic test results for rs61764370 should not be used to counsel women 
about their ovarian or breast cancer risks or outcome. Our results highlight the dangers of 
developing clinical tests without appropriate data from carefully conducted, large-scale studies to 
establish clinical validity.  
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TABLE LEGENDS 
Table 1.  Associations between KRAS rs61764370 and risk of ovarian and breast cancer. 
For BRCA1 and BRCA2 mutation carrier analyses, cases are affected BRCA1/BRCA2 mutation 
carriers and controls are unaffected BRCA1/BRCA2 mutation carriers, and relative risks are 
estimated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; ovarian 
cancer analyses used OCAC data adjusted for study, age, and the five European principal 
components; breast cancer analyses used BCAC data adjusted for study, age, and the seven 
European principal components; BRCA1 and BRCA2 mutation carrier analyses used CIMBA data 
with age as follow-up time and stratified for country; 95% CI, 95% confidence interval.  
 
Table 2.  Associations between KRAS rs61764370 and outcome in ovarian and breast 
cancer. 
Ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the 
five European principal components, histology (serous, mucinous, endometrioid, clear cell, and 
other epithelial), grade (low versus high), FIGO stage (I-IV), residual disease after debulking 
surgery (nil versus any), and stratified by study; breast cancer analyses used BCAC data adjusted 
for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy and 
was stratified by study; analyses for BRCA1 and BRCA2 mutation carriers used CIMBA data 
adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or 
chemotherapy, and preventive bilateral oophorectomy and was stratified by study; 95% CI, 95% 
confidence interval.  
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FIGURE LEGENDS 
Figure 1. Regional association plots for variants within the genomic region 100 kb either 
side of KRAS and risk of ovarian and breast cancer.  
X-axis position is referent to position (bp) on chromosome 12, build GRCh37.p12; yellow line 
indicates position of KRAS; red triangle indicates rs61764370. Y-axis is –log10(p-values) from 
association tests for risk of A) Epithelial ovarian cancer risk, B) Epithelial ovarian cancer risk: 
BRCA1 mutation carriers, C) Epithelial ovarian cancer risk: BRCA2 mutation carriers, D) ER- 
negative breast cancer risk E) ER+ positive breast cancer F) Breast cancer risk: BRCA1 mutation 
carriers G) Breast cancer risk: BRCA2 mutation carriers. 
 
Figure 2. Power curve for modest risk variants according to the total sample size.  
X-axis is total sample size for which case-control ratio is 1:1. Y- axis is the statistical power (range 
0·5-1·0) for variants given a range of risks, assuming alpha=0·01 and minor allele frequency 0·09. 
